Q-omics provides the consensus-scored MEST profile across patient tissues and cancer cell-line models. MEST expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MEST is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MEST RNA expression shows 18,631 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where MEST shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEST — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEST survival associations across molecular data types. MEST RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEST RNA expression–survival associations across cancer types. High MEST expression shows unfavorable associations in ACC, CESC, KIRC, LGG and BLCA, but favorable associations in LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MEST RNA expression.
This table summarizes MEST tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MEST. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEST shows lower tumor expression in KIRC and KICH and higher tumor expression in BLCA, HNSC, COAD and STAD. The KIRC box plot shows higher MEST RNA expression in normal versus tumor tissue (log2 FC = −1.836, t-test p < 0.001).
This table shows molecular features associated with MEST in patient tissues and cancer cell lines. In patient samples, MEST shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MEST RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
